ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,
Part 4 – Biological Products

COVID-19 Vaccines

COVID-19 Vaccine Eligibility

- Content has been added to indicate that individuals 5 to 11 years of age who are moderately to severely immunosuppressed should receive a 3-dose primary series.
- Content has been added to indicate that Moderna COVID-19 vaccine is preferentially recommended as the booster dose for individuals 18-69 years of age who are moderately to severely immunosuppressed.
- Individuals 12 to 17 years of age have been added as eligible for a booster dose, with a link to the B.C. government website for those who are at higher risk of severe illness and should receive a booster dose.

COVID-19 mRNA Vaccine COMIRNATY® (Pfizer-BioNTech) (Adult/Adolescent)

- Doses and Schedule:
  - Content has been revised to indicate that individuals 12 years of age and older are eligible for a booster dose.

- Booster Doses:
  - A table has been added to provide clarity on preferential recommendations regarding booster doses.

Please add new page numbers: 1-6 dated February 3, 2022
COVID-19 mRNA Vaccine COMIRNATY® (Pfizer-BioNTech) (Pediatric)

- **Doses and Schedule:**
  - Content has been added to indicate that individuals who are moderately to severely immunosuppressed should receive a 3-dose primary series.

- **Administration:**
  - Footnote B has been updated to reflect an expiry date extension from 6 months to 9 months provided storage temperature has been maintained at -90°C to -60°C.

Please remove page numbers: 1-6 dated January 21, 2022
Please add new page numbers: 1-6 dated February 3, 2022

COVID-19 mRNA Vaccine Vaccine SPIKEVAX™ (Moderna)

- **Doses and Schedule:**
  - Content has been revised to indicate that individuals 12 years of age and older are eligible for a booster dose.

- **Booster Doses:**
  - A table has been added to provide clarity on preferential recommendations regarding booster doses.
  - Footnote B has been added to indicate that age-based booster dosing recommendations apply to Moderna COVID-19 booster doses for moderately to severely immunosuppressed clients.

Please remove page numbers: 1-5 dated January 21, 2022
Please add new page numbers: 1-5 dated February 3, 2022
If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,

Monika Naus MD MHSc FRCPC FACPM
Medical Director
Communicable Diseases & Immunization Service
BC Centre for Disease Control

pc:
- Provincial Health Officer
  - Dr. Bonnie Henry
- Dr. Reka Gustafson
  - Vice President, Public Health & Wellness, PHSA & Deputy Provincial Health Officer
- Deputy Provincial Health Officer
  - Dr. Martin Lavoie

BC Ministry of Health, Population & Public Health Division:
- Brian Sagar
  - Senior Director Communicable Disease, Population and Public Health Division
- Bernard Achampong
  - Executive Director, Public Health, Planning and Prevention, Population and Public Health Division